Simak Ali
Tue 19
Session VII: Novel therapeutic targets
Therapeutic targeting of gene regulatory processes in breast cancer
Steve Balk
Beth Israel Deaconess Medical Center, Boston
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
Persistent AR activity in enzalutamide resistant prostate cancer?
Beth Israel Deaconess Medical Center, Boston
Jyotsna Batra
IHBI, Brisbane
Wed 20
Inaugural “Rob Sutherland Award”
A GWAS identified functional variation in PSA (KLK3) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with prostate cancer
IHBI, Brisbane
Professor Charlotte Bevan
London, UK
Tue 19
Session VII: Novel therapeutic targets
MicroRNAs: a potential new therapeutic avenue
London, UK
Kara Britt
Peter MacCallum Cancer Centre, Melbourne
Wed 20
Inaugural “Rob Sutherland Award”
Estrogen receptor positive luminal progenitors the cancer cell of origin for estrogen receptor positive breast cancer
Peter MacCallum Cancer Centre, Melbourne
Lisa Butler
University of Adelaide / SAHMRI, Adelaide
Wed 20
Session X: Cellular homeostasis
Membrane lipid remodelling: untapped opportunities to predict and disrupt metastasis of hormone-dependent cancers
University of Adelaide / SAHMRI, Adelaide
Liz Caldon
Garvan Institute of Medical Research, Sydney
Sun 17
Flash talks
Mechanisms underlying uncontrolled genome doubling in breast cancer
Garvan Institute of Medical Research, Sydney
Wed 20
Inaugural “Rob Sutherland Award”
Mechanisms underlying uncontrolled genome doubling in breast cancer
Garvan Institute of Medical Research, Sydney
Jason Carroll
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
How many associated proteins? What ones are important?
Aurélie Cazet
Garvan Institute of Medical Research, Sydney
Sun 17
Flash talks
Targeting stromal remodelling and cancer stem cell plasticity overcomes chemoresistance in metastatic triple negative breast cancer
Garvan Institute of Medical Research, Sydney
Christine Chaffer
Garvan Institute of Medical Research, Sydney
Wed 20
Session XI: Building a rabbit proof fence: the tumour “terroir”
Cancer cell plasticity drives the development of chemoresistance in breast cancer
Garvan Institute of Medical Research, Sydney
Sara Charmsaz
Royal College of Surgeons in Ireland, Dublin
Sun 17
Flash talks
Epi-transcriptomic alterations in ER-positive breast cancer
Royal College of Surgeons in Ireland, Dublin
Frank Claessens
KU Leuven University, Leuven
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
Live from an androgen receptor lab: some old news revisited
KU Leuven University, Leuven
Melissa Davis
Walter and Eliza Hall Institute, Melbourne
Wed 20
Inaugural “Rob Sutherland Award”
Combinatorial co-targeting by miRNAs: a subtle but strong regulator of epithelial-mesenchymal transitions
Walter and Eliza Hall Institute, Melbourne
Scott Dehm
University of Minnesota, Minneapolis
Mon 18
Session III: Endocrine resistance – common mechanisms?
Endocrine uncoupling: When androgen receptors are no longer receptors
University of Minnesota, Minneapolis
Anita Dunbier
University of Otago, Dunedin
Mon 18
Session VI: Harnessing the immune system
Immune involvement and therapies in ER-positive breast cancer
University of Otago, Dunedin
Patricia Elizalde
Institut de Biologica y Medicina Experimental, Buenos Aires
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
My name is ErbB-2, I will be called a transcription factor
Institut de Biologica y Medicina Experimental, Buenos Aires
Leigh Ellis
Dana Farber Cancer Institute, Boston
Mon 18
Session V: Cell plasticity and tumorigenesis
Exploiting RB1 deficiency for novel therapeutic targets in prostate cancer
Dana Farber Cancer Institute, Boston
Felix Feng
University of California, San Francisco
Sun 17
Session I: Breast and prostate cancer - more similar than different
Basal vs luminal molecular subtyping in breast and prostate cancer: Implications for treatment selection
University of California, San Francisco
Liesel FitzGerald
Menzies Institute for Medical Research, Hobart
Sun 17
Flash talks
Array comparative genomic hybridisation of familial prostate cancer tumours identifies a recurrent copy number gain on chr19p13.3 encompassing the EEF2 gene
Menzies Institute for Medical Research, Hobart
Luc Furic
Peter MacCallum Cancer Centre, Melbourne
Sun 17
Flash talks
Estrogen receptor alpha controls gene expression via translational offsetting
Peter MacCallum Cancer Centre, Melbourne
Vincent Giguère
McGill University, Montreal
Wed 20
Session X: Cellular homeostasis
The AR/mTOR/DNA-PK nuclear complexes: the missing links in prostate cancer?
McGill University, Montreal
Andrei Goga
University of California, San Francisco
Tue 19
Session VII: Novel therapeutic targets
New metabolic and mitotic targets in TNBC
University of California, San Francisco
Geof Greene
University of Chicago, Chicago
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
Unexpected therapeutic efficacy of a SERM in mutant ER breast cancer
University of Chicago, Chicago
Phil Gregory
Centre for Cancer Biology, Adelaide
Wed 20
Inaugural “Rob Sutherland Award”
Estrogen receptor regulated miR-342 suppresses a pro-metastatic gene network
Centre for Cancer Biology, Adelaide
Gavin Ha
Fred Hutchinson Cancer Research Centre, Seattle
Mon 18
Session IV: Other ‘omics
Profiling whole cancer genomes from circulating tumor DNA
Fred Hutchinson Cancer Research Centre, Seattle
Housheng He
University of Toronto, Toronto
Mon 18
Session IV: Other ‘omics
Transcriptomic and functional landscape of circular RNA in prostate and breast cancer
University of Toronto, Toronto
Theresa Hickey
DRMCRL, Adelaide
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
When is AR oncogenic in breast cancer?
DRMCRL, Adelaide
Dietmar Hutmacher
Institute of Health and Biomedical Innovation QUT, Brisbane
Tue 19
Session VIII: New instruments in the breast and prostate cancer symphony
Convergence of regenerative medicine principles to develop new breast and prostate cancer mice models
Institute of Health and Biomedical Innovation QUT, Brisbane
Richard Iggo
University of Bordeaux, Bordeaux
Tue 19
Session VIII: New instruments in the breast and prostate cancer symphony
What I cannot create, I do not understand: are MIND models the answer?
University of Bordeaux, Bordeaux
Rinath Jeselsohn
Dana Farber Cancer Institute, Boston
Mon 18
Session III: Endocrine resistance – common mechanisms?
Endocrine resistance: The most common clinical mechanism
Dana Farber Cancer Institute, Boston
Manav Korpal
H3 Biomedicine Inc, Cambridge MA
Mon 18
Session III: Endocrine resistance – common mechanisms?
Discovery and development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT/MUTb breast cancer
H3 Biomedicine Inc, Cambridge MA
Natasha Kyprianou
University of Kentucky, Lexington
Mon 18
Session V: Cell plasticity and tumorigenesis
Androgen interference with prostate cancer response to Cabazitaxel
University of Kentucky, Lexington
Mitchell Lawrence
Monash University, Melbourne
Sun 17
Flash talks
New combination therapies for castration-resistant prostate cancer
Monash University, Melbourne
Adrian Lee
UPMC, Pittsburgh
Sun 17
Session I: Breast and prostate cancer - more similar than different
Overcoming inter-patient heterogeneity – intra-patient analysis of breast cancer evolution
UPMC, Pittsburgh
Jason Lee
QIMR Berghofer, Brisbane
Wed 20
Session XI: Building a rabbit proof fence: the tumour “terroir”
Harnessing the epigenome: a handbrake for metastasis
QIMR Berghofer, Brisbane
Geoff Lindeman
Walter and Eliza Hall Institute, Melbourne
Tue 19
Session VII: Novel therapeutic targets
Targeting cell survival pathways in breast cancer using BH3 mimetics
Walter and Eliza Hall Institute, Melbourne
Luca Magnani
Imperial College London, London
Mon 18
Session III: Endocrine resistance – common mechanisms?
Endocrine resistance – common mechanisms? Not really. To each its own, a single cell tale of resistance
Imperial College London, London
Amy McCart-Reed
UQ Centre for Clinical Research, Brisbane
Sun 17
Flash talks
LobSig, a prognostic signature for ILC 22
UQ Centre for Clinical Research, Brisbane
Donald McDonnell
Duke University School of Medicine, Durham
Wed 20
Session X: Cellular homeostasis
Dyslipidemia and breast cancer pathobiology
Duke University School of Medicine, Durham
Ian Mills
Oxford University / Queen's University of Belfast, Oxford
Wed 20
Session X: Cellular homeostasis
Contributions of the unfolded protein response and glycosylation to homeostasis
Oxford University / Queen's University of Belfast, Oxford
Pete Nelson
Fred Hutchinson Cancer Research Centre, Seattle
Wed 20
Session XI: Building a rabbit proof fence: the tumour “terroir”
Intrinsic and extrinsic drivers of micro- and macro-metastasis
Fred Hutchinson Cancer Research Centre, Seattle
Sam Oakes
Garvan Institute of Medical Research, Sydney
Sun 17
Flash talks
Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer
Garvan Institute of Medical Research, Sydney
David Ortega
Garvan Institute of Medical Research, Sydney
Tue 19
Session VIII: New instruments in the breast and prostate cancer symphony
A novel biomimetic tissue engineering platform to understand molecular mechanisms of drug resistance at single cell resolution
Garvan Institute of Medical Research, Sydney
Steffi Osterreich
University of Pittsburgh, Pittsburgh
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
Estrogen receptor alterations - the most frequent cause of death from breast cancer?
University of Pittsburgh, Pittsburgh
Carlo Palmieri
University of Liverpool, Liverpool
Mon 18
Session VI: Harnessing the immune system
Immunotherapy for breast cancer: challenges and opportunities
University of Liverpool, Liverpool
Belinda Parker
La Trobe Institute for Molecular Science, Melbourne
Mon 18
Session VI: Harnessing the immune system
Reversing tumour invisibility in bone to combat metastatic disease
La Trobe Institute for Molecular Science, Melbourne
Richard Pestell
Baruch S Blumberg Institute, Philadelphia
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
DACH1 gene deletion extends portraits of human prostate cancer
Baruch S Blumberg Institute, Philadelphia
David Quinn
USC Norris Comprehensive Cancer Center, Los Angeles
Mon 18
Session VI: Harnessing the immune system
Role of tumor blood vessels and response to check point inhibitors
USC Norris Comprehensive Cancer Center, Los Angeles
Ganesh Raj
UT Southwestern Medical Centre, Dallas
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
Overcoming endocrine resistance: masterminds, metaphors and mutants
UT Southwestern Medical Centre, Dallas
Oscar Rueda
CRUK, Cambridge
Sun 17
Session I: Breast and prostate cancer - more similar than different
Statistical approaches to personalised medicine in breast cancer
CRUK, Cambridge
Shahneen Sandhu
Peter MacCallum Cancer Centre, Melbourne
Mon 18
Session VI: Harnessing the immune system
Immunotherapy in prostate cancer: challenges and progress
Peter MacCallum Cancer Centre, Melbourne
Carol Sartorius
University of Colorado, Denver
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
PR-RAR crosstalk in breast cancer
University of Colorado, Denver
Theresa Selth
DRMCRL, Adelaide
Sun 17 13:15
Breast and prostate cancer - more similar than different
Breast and prostate cancer - more similar than different
DRMCRL, Adelaide
Luke Selth
DRMCRL, Adelaide
Wed 20
Inaugural “Rob Sutherland Award”
A miR-194-regulated transcriptional network is associated with progression to androgen receptor-independent prostate cancer
DRMCRL, Adelaide
Violeta Serra
VHIO - Vall Hebron Institute of Oncology, Barcelona
Tue 19
Session VIII: New instruments in the breast and prostate cancer symphony
Challenges and opportunities using ER-positive patient-derived tumour xenoimplant models
VHIO - Vall Hebron Institute of Oncology, Barcelona
Rasmus Siersbaek
CRUK, Cambridge
Wed 20
Inaugural “Rob Sutherland Award”
IL6/STAT3 co-opts ER regulatory elements to drive metastasis in breast cancer
CRUK, Cambridge
Cameron Snell
Mater Research Institute, Brisbane
Sun 17
Flash talks
Exploring the clinical significance of interactions between oestrogen and progesterone receptors in breast and endometrioid adenocarcinomas by proximity ligation assay
Mater Research Institute, Brisbane
Janet Stanford
Fred Hutchinson Cancer Research Centre, Seattle
Sun 17
Session I: Breast and prostate cancer - more similar than different
Genetic susceptibility and risk stratification for prostate cancer screening and prevention
Fred Hutchinson Cancer Research Centre, Seattle
Alex Swarbrick
Garvan Institute of Medical Research, Sydney
Mon 18
Session IV: Other ‘omics
Multi-dimensional single cell analysis of the tumour microenvironment
Garvan Institute of Medical Research, Sydney
David Thomas
Broad Institute, Boston
Wed 20
Session X: Cellular homeostasis
Aggressive cancer homeostasis through dynamic flux
Broad Institute, Boston
Jane Visvader
Walter and Eliza Hall Institute, Melbourne
Mon 18
Session V: Cell plasticity and tumorigenesis
Dissecting intraclonal plasticity during breast oncogenesis
Walter and Eliza Hall Institute, Melbourne
Leonie Young
Royal College of Surgeons in Ireland, Dublin
Wed 20
Session XI: Building a rabbit proof fence: the tumour “terroir”
Understanding the transcriptomic circulatory – blocking the rabbit holes early
Royal College of Surgeons in Ireland, Dublin
Amina Zoubeidi
University of British Columbia, Vancouver
Mon 18
Session V: Cell plasticity and tumorigenesis
Cell plasticity in treatment resistant prostate cancer
University of British Columbia, Vancouver
Wilbert Zwart
Netherlands Cancer Institute, Amsterdam
Mon 18
Session IV: Other ‘omics
Cistromics in clinical trials: Mechanistic insights in tumorigenesis and disease progression?
Netherlands Cancer Institute, Amsterdam
Sun 17 11:00
Registration and poster set-up
Sun 17 13:00
Welcome - Wayne Tilley (DRMCRL, University of Adelaide, Adelaide)
Sun 17 13:15
Breast and prostate cancer - more similar than different
Breast and prostate cancer - more similar than different
DRMCRL, Adelaide
Sun 17
Session I: Breast and prostate cancer - more similar than different
Genetic susceptibility and risk stratification for prostate cancer screening and prevention
Fred Hutchinson Cancer Research Centre, Seattle
Sun 17
Session I: Breast and prostate cancer - more similar than different
Statistical approaches to personalised medicine in breast cancer
CRUK, Cambridge
Sun 17
Session I: Breast and prostate cancer - more similar than different
Basal vs luminal molecular subtyping in breast and prostate cancer: Implications for treatment selection
University of California, San Francisco
Sun 17
Session I: Breast and prostate cancer - more similar than different
Overcoming inter-patient heterogeneity – intra-patient analysis of breast cancer evolution
UPMC, Pittsburgh
Sun 17
Session I: Breast and prostate cancer - more similar than different
General discussion (40–45 minutes)
Sun 17 15:00
Break
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
Estrogen receptor alterations - the most frequent cause of death from breast cancer?
University of Pittsburgh, Pittsburgh
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
Overcoming endocrine resistance: masterminds, metaphors and mutants
UT Southwestern Medical Centre, Dallas
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
When is AR oncogenic in breast cancer?
DRMCRL, Adelaide
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
Persistent AR activity in enzalutamide resistant prostate cancer?
Beth Israel Deaconess Medical Center, Boston
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
Unexpected therapeutic efficacy of a SERM in mutant ER breast cancer
University of Chicago, Chicago
Sun 17
Session II: Estrogen and androgen receptors: still key drivers?
General discussion (40–45 minutes)
Sun 17
Flash talks
Mechanisms underlying uncontrolled genome doubling in breast cancer
Garvan Institute of Medical Research, Sydney
Sun 17
Flash talks
Targeting stromal remodelling and cancer stem cell plasticity overcomes chemoresistance in metastatic triple negative breast cancer
Garvan Institute of Medical Research, Sydney
Sun 17
Flash talks
Epi-transcriptomic alterations in ER-positive breast cancer
Royal College of Surgeons in Ireland, Dublin
Sun 17
Flash talks
Array comparative genomic hybridisation of familial prostate cancer tumours identifies a recurrent copy number gain on chr19p13.3 encompassing the EEF2 gene
Menzies Institute for Medical Research, Hobart
Sun 17
Flash talks
Estrogen receptor alpha controls gene expression via translational offsetting
Peter MacCallum Cancer Centre, Melbourne
Sun 17
Flash talks
New combination therapies for castration-resistant prostate cancer
Monash University, Melbourne
Sun 17
Flash talks
LobSig, a prognostic signature for ILC 22
UQ Centre for Clinical Research, Brisbane
Sun 17
Flash talks
Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer
Garvan Institute of Medical Research, Sydney
Sun 17
Flash talks
Exploring the clinical significance of interactions between oestrogen and progesterone receptors in breast and endometrioid adenocarcinomas by proximity ligation assay
Mater Research Institute, Brisbane
Sun 17 18:00
“Ron Ross Award” Oration – Dr Funmi Olopade, MD, University of Chicago Medicine, Chicago
Chairs: Wayne Tilley & Elgene Lim
Sun 17 19:15
Welcome reception
Mon 18 07:00
Breakfast
Mon 18
Session III: Endocrine resistance – common mechanisms?
Endocrine resistance: The most common clinical mechanism
Dana Farber Cancer Institute, Boston
Mon 18
Session III: Endocrine resistance – common mechanisms?
Endocrine resistance – common mechanisms? Not really. To each its own, a single cell tale of resistance
Imperial College London, London
Mon 18
Session III: Endocrine resistance – common mechanisms?
Endocrine uncoupling: When androgen receptors are no longer receptors
University of Minnesota, Minneapolis
Mon 18
Session III: Endocrine resistance – common mechanisms?
Discovery and development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT/MUTb breast cancer
H3 Biomedicine Inc, Cambridge MA
Mon 18
Session III: Endocrine resistance – common mechanisms?
General discussion (40–45 minutes)
Mon 18 10:00
Break
Mon 18
Session IV: Other ‘omics
Transcriptomic and functional landscape of circular RNA in prostate and breast cancer
University of Toronto, Toronto
Mon 18
Session IV: Other ‘omics
Profiling whole cancer genomes from circulating tumor DNA
Fred Hutchinson Cancer Research Centre, Seattle
Mon 18
Session IV: Other ‘omics
Cistromics in clinical trials: Mechanistic insights in tumorigenesis and disease progression?
Netherlands Cancer Institute, Amsterdam
Mon 18
Session IV: Other ‘omics
Multi-dimensional single cell analysis of the tumour microenvironment
Garvan Institute of Medical Research, Sydney
Mon 18
Session IV: Other ‘omics
General discussion (40–45 minutes)
Mon 18 12:00
Lunch
Mon 18
Session V: Cell plasticity and tumorigenesis
Exploiting RB1 deficiency for novel therapeutic targets in prostate cancer
Dana Farber Cancer Institute, Boston
Mon 18
Session V: Cell plasticity and tumorigenesis
Cell plasticity in treatment resistant prostate cancer
University of British Columbia, Vancouver
Mon 18
Session V: Cell plasticity and tumorigenesis
Androgen interference with prostate cancer response to Cabazitaxel
University of Kentucky, Lexington
Mon 18
Session V: Cell plasticity and tumorigenesis
Dissecting intraclonal plasticity during breast oncogenesis
Walter and Eliza Hall Institute, Melbourne
Mon 18
Session V: Cell plasticity and tumorigenesis
General discussion (40–45 minutes)
Mon 18 15:00
Break
Mon 18
Session VI: Harnessing the immune system
Immunotherapy in prostate cancer: challenges and progress
Peter MacCallum Cancer Centre, Melbourne
Mon 18
Session VI: Harnessing the immune system
Immune involvement and therapies in ER-positive breast cancer
University of Otago, Dunedin
Mon 18
Session VI: Harnessing the immune system
Reversing tumour invisibility in bone to combat metastatic disease
La Trobe Institute for Molecular Science, Melbourne
Mon 18
Session VI: Harnessing the immune system
Role of tumor blood vessels and response to check point inhibitors
USC Norris Comprehensive Cancer Center, Los Angeles
Mon 18
Session VI: Harnessing the immune system
Immunotherapy for breast cancer: challenges and opportunities
University of Liverpool, Liverpool
Mon 18
Session VI: Harnessing the immune system
General discussion (40–45 minutes)
Mon 18 19:00
Dinner
Tue 19 07:00
Breakfast
Tue 19
Session VII: Novel therapeutic targets
MicroRNAs: a potential new therapeutic avenue
London, UK
Tue 19
Session VII: Novel therapeutic targets
New metabolic and mitotic targets in TNBC
University of California, San Francisco
Tue 19
Session VII: Novel therapeutic targets
Therapeutic targeting of gene regulatory processes in breast cancer
Tue 19
Session VII: Novel therapeutic targets
Targeting cell survival pathways in breast cancer using BH3 mimetics
Walter and Eliza Hall Institute, Melbourne
Tue 19
Session VII: Novel therapeutic targets
General discussion (40–45 minutes)
Tue 19 10:00
Break
Tue 19
Session VIII: New instruments in the breast and prostate cancer symphony
A novel biomimetic tissue engineering platform to understand molecular mechanisms of drug resistance at single cell resolution
Garvan Institute of Medical Research, Sydney
Tue 19
Session VIII: New instruments in the breast and prostate cancer symphony
What I cannot create, I do not understand: are MIND models the answer?
University of Bordeaux, Bordeaux
Tue 19
Session VIII: New instruments in the breast and prostate cancer symphony
Challenges and opportunities using ER-positive patient-derived tumour xenoimplant models
VHIO - Vall Hebron Institute of Oncology, Barcelona
Tue 19
Session VIII: New instruments in the breast and prostate cancer symphony
Convergence of regenerative medicine principles to develop new breast and prostate cancer mice models
Institute of Health and Biomedical Innovation QUT, Brisbane
Tue 19
Session VIII: New instruments in the breast and prostate cancer symphony
General discussion (40–45 minutes)
Tue 19 12:00
Lunch
Tue 19 13:00
Free time
Tue 19 16:30
Poster session
Tue 19 19:00
Dinner
Tue 19
The Great Debate – “Are humans the only model?”
Moderator: Chris Sweeney. For: Alex Swarbrick (Team Captain), Melissa Davis, Scott Dehm, Luca Magnani, Steffi Oesterreich, Amina Zoubeidi. Against: Carol Lange (Team Captain), Charlotte Bevan, Steve Birrell, Donald McDonnell, Sam Oakes, Wilbert Zwart. Judges: Suzanne Fuqua, Geof Greene, Gail Prins, Gail Risbridger
Wed 20 07:00
Breakfast
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
How many associated proteins? What ones are important?
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
Live from an androgen receptor lab: some old news revisited
KU Leuven University, Leuven
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
PR-RAR crosstalk in breast cancer
University of Colorado, Denver
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
DACH1 gene deletion extends portraits of human prostate cancer
Baruch S Blumberg Institute, Philadelphia
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
My name is ErbB-2, I will be called a transcription factor
Institut de Biologica y Medicina Experimental, Buenos Aires
Wed 20
Session IX: Nuclear receptors and co-regulators: What’s new?
General discussion (40–45 minutes)
Wed 20 10:00
Break
Wed 20
Session X: Cellular homeostasis
Contributions of the unfolded protein response and glycosylation to homeostasis
Oxford University / Queen's University of Belfast, Oxford
Wed 20
Session X: Cellular homeostasis
Aggressive cancer homeostasis through dynamic flux
Broad Institute, Boston
Wed 20
Session X: Cellular homeostasis
Membrane lipid remodelling: untapped opportunities to predict and disrupt metastasis of hormone-dependent cancers
University of Adelaide / SAHMRI, Adelaide
Wed 20
Session X: Cellular homeostasis
The AR/mTOR/DNA-PK nuclear complexes: the missing links in prostate cancer?
McGill University, Montreal
Wed 20
Session X: Cellular homeostasis
Dyslipidemia and breast cancer pathobiology
Duke University School of Medicine, Durham
Wed 20
Session X: Cellular homeostasis
General discussion (40–45 minutes)
Wed 20 12:00
Lunch
Wed 20
Session XI: Building a rabbit proof fence: the tumour “terroir”
Understanding the transcriptomic circulatory – blocking the rabbit holes early
Royal College of Surgeons in Ireland, Dublin
Wed 20
Session XI: Building a rabbit proof fence: the tumour “terroir”
Intrinsic and extrinsic drivers of micro- and macro-metastasis
Fred Hutchinson Cancer Research Centre, Seattle
Wed 20
Session XI: Building a rabbit proof fence: the tumour “terroir”
Harnessing the epigenome: a handbrake for metastasis
QIMR Berghofer, Brisbane
Wed 20
Session XI: Building a rabbit proof fence: the tumour “terroir”
Cancer cell plasticity drives the development of chemoresistance in breast cancer
Garvan Institute of Medical Research, Sydney
Wed 20
Session XI: Building a rabbit proof fence: the tumour “terroir”
General discussion (40–45 minutes)
Wed 20 14:45
Break
Wed 20
Inaugural “Rob Sutherland Award”
A GWAS identified functional variation in PSA (KLK3) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with prostate cancer
IHBI, Brisbane
Wed 20
Inaugural “Rob Sutherland Award”
Estrogen receptor positive luminal progenitors the cancer cell of origin for estrogen receptor positive breast cancer
Peter MacCallum Cancer Centre, Melbourne
Wed 20
Inaugural “Rob Sutherland Award”
Mechanisms underlying uncontrolled genome doubling in breast cancer
Garvan Institute of Medical Research, Sydney
Wed 20
Inaugural “Rob Sutherland Award”
Combinatorial co-targeting by miRNAs: a subtle but strong regulator of epithelial-mesenchymal transitions
Walter and Eliza Hall Institute, Melbourne
Wed 20
Inaugural “Rob Sutherland Award”
Estrogen receptor regulated miR-342 suppresses a pro-metastatic gene network
Centre for Cancer Biology, Adelaide
Wed 20
Inaugural “Rob Sutherland Award”
A miR-194-regulated transcriptional network is associated with progression to androgen receptor-independent prostate cancer
DRMCRL, Adelaide
Wed 20
Inaugural “Rob Sutherland Award”
IL6/STAT3 co-opts ER regulatory elements to drive metastasis in breast cancer
CRUK, Cambridge
Wed 20 16:30
Meeting close
Wed 20 19:00
Conference dinner

0 result(s) found.